Back to Products
32mg
Retatrutide 32 Pen
Pre-filled research pen with 32mg of Retatrutide, a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors. Supplied by BodyPharm across Metro Manila and the wider Philippines. For research purposes only.
Our Retatrutide 32 Pen is imported from Dubai in sealed, sterile cartridges, the same research-grade product we supply across the UAE. Unlike locally compounded pens, every cartridge arrives factory-sealed and untouched. Priced in PHP with delivery across the Philippines.
Specifications
A custom volume selector, with increments calibrated to this specific peptide.
2
Drag or tap to plan doses
The dose dial is printed on the pen. Just click up to the volume you want, and the number you land on is the dose delivered.
≥99%
Purity · HPLC
2 to 8°C
Refrigerated
Pre-filled pen
Format
Janoshik
Verified
Retatrutide · LY3437943
CAS 2381089-83-2 · ~4731 g/mol
CAS 2381089-83-2 · ~4731 g/mol
Certificate of Analysis
Verified by independent & in-house laboratory testing
Janoshik Analytical
Independent third-party laboratory
99.4%
purity
Batch RET4683
Report #106564
06 Feb 2026
Body Pharm lab
Body Pharm laboratory
98.75%
purity
Batch RET3254
Report #20251011
14.06 mg/ml
Research Areas
Designed for advanced research in these areas
01
Metabolic pathway modulation studies
02
Body composition & energy expenditure research
03
Appetite signalling mechanism analysis
04
Multi-receptor agonist pharmacology
A sealed cartridge, not a compounded pen
Your Retatrutide is a sealed, factory-filled cartridge, not product drawn from a vial into a pen by hand. Here is what that means.
Fill method
Our pens
BodyPharm
Sealed at the facility
Dosed and capped at fill, never opened.
Elsewhere
Mixed by hand
Vial drawn into a cartridge by hand.
Research Background
Retatrutide (LY3437943) engages three metabolic receptors at once.
GIPR
GIP receptor
GLP-1R
GLP-1 receptor
GCGR
glucagon
The glucagon (GCGR) component draws the most interest, in lab models its activation is linked to hepatic glucose output, thermogenesis, and hepatic fat changes relevant to NAFLD/MASH studies.
Research reference
Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med 2023;389:514-26 →
Precision Engineered
Retatrutide is an investigational triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation, energy expenditure, and body composition research.
✓Triple-receptor agonist, GLP-1, GIP, and glucagon pathways
✓Extended half-life for stable pharmacokinetic profiles
✓Subject of multiple ongoing clinical trials
✓Pre-filled pen for precise, repeatable delivery
✓Janoshik-verified, ≥99% purity guaranteed
What Researchers Say
How was our customer service? Did your delivery arrive on time? Was the product what you expected? Let us know and receive 10% off and free delivery with your next order.
Frequently Asked Questions
Retatrutide (LY3437943) is an investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors. For laboratory research only.
Ready to order?
Retatrutide 32 Pen
Unavailable
Fast, secure cold-chain delivery
Imported from DubaiSealed sterile cartridgesMetro Manila delivery